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Abstract
Background: Matrix-producing carcinoma (MPC) of the breast is one variant type of metaplastic
carcinoma. The cellular origin of MPC remains unclear. It has been suggested the tumor cells in
MPC have the combined characteristics of both epithelial cells and mesenchymal cells. Several
reports suggested that the tumor cells in MPC might originate from the myoepithelial cells, but
others suggested the origin was basal-like cells.
Case presentation: The patient was a 42-year-old Japanese female. A tumor of about 2 cm in
diameter was noted in the right breast. CT revealed the circumference of the tumor to have a ring-
like structure, and fine needle aspiration cytology indicated suspicion for malignancy. Breast-
conserving surgery was performed. Histopathological studies showed carcinoma cells, having
cuboidal to oval-shaped nucleus, were proliferating in cord-like and sheet-like structures in the
periphery. In the central areas of the tumor, myxoedematous area was observed with cartilaginous
matrix and necrosis. The diagnosis was a matrix-producing carcinoma. Immunohistochemical
findings showed the tumor cells had the characteristics of both epithelial cells and mesenchymal
cells, while being negative for estrogen receptor, progesterone receptor, Her2, myoepithelial cell
markers and basal cell markers.
Conclusion: The findings for our present patient and many of the other MPC patients reported
in the published literature indicate that this breast cancer has the properties of both epithelial cells
and mesenchymal cells. In addition, there is a possibility that matrix-producing tumor cells of our
present patient may have a feature of undifferentiated cells.
Background
Matrix-producing carcinoma (MPC) is a rare and charac-
teristic variant type of metaplastic carcinoma of the breast.
In 1989, Wargotz et al., proposed defining MPC as overt
carcinoma with direct transition to a cartilaginous and/or
osseous stromal matrix cells, with no spindle cells
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between those two elements [1]. In Japan, MPC of the
breast was added to the General Rules for Clinical and
Pathological Recording of breast Cancer (16th  Edi-
tion)(The Japanese Breast Cancer Society) as a special
form of carcinoma [2]. It was reported that MPC cells had
the combined characteristics of both epithelial cells and
mesenchymal cells [3-5]. Wargotz et al., suggested the
tumor cells of MPC might be of epithelial-myoepithelial
derivation depending on immunohistochemical analysis
and electron microscopic results [1]. In addition, mouse
model using Brca1 deficiency has suggested an important
role for BRCA1 in basal-like breast carcinoma with meta-
plastic elements [6]. There is thus no consensus in his-
togenesis of MPC. We report our findings for a Japanese
woman with MPC of the breast and discuss them together
with the other 26 cases of MPC of the breast that have
been reported in Japan to date.
Case presentation
The patient was a 42-year-old Japanese female with a chief
complaint of a lump in her right breast. Her personal and
family histories contained nothing of special note.
Examination revealed a hard tumor with a clear boundary
and a diameter of about 2 cm in the lateral-upper quad-
rant of the right breast. The axillary and supraclavicular
lymph nodes could not be palpated. Mammography
revealed focal asymmetric density in the right lateral-
upper quadrant, accompanied by amorphous microcalci-
fication. Breast echography indicated a tumor with
dimensions of 2.3 × 1.8 × 1.5 cm and a slightly indistinct
boundary, and the internal portion was heterogeneous
and included a hyperechoic region. Contrast-enhanced
CT revealed, in the right lateral-upper quadrant, an irreg-
ularly shaped, 2.5 cm tumor showing peripheral ring-
shaped contrast enhancement (Fig. 1). There was no evi-
dence of lymph node metastasis or clear distant metasta-
sis. Aspiration cytology showed many tumor cells, having
cuboidal to oval-shaped nucleus, were observed in the
myxoedematous background containing much necrotic
material, but without any sarcomatous spindle cells. The
myxoedematous matrix in the background stained pale
gray with Papanicolau stain. The tumor cells were iso-
lated, in loosely cohesive groups and in short chains. The
nuclear to cytoplasmic ratio was high with coarsely gran-
ular chromatin. The diagnosis was suspicious for malig-
nancy. No particular abnormalities were noted on
laboratory data, and tumor markers were all within their
normal ranges: 1.6 ng/ml for CEA and 19 ng/ml for CA
15-3. Right breast cancer was suspected on the basis of the
above findings, and lumpectomy was performed.
Histopathological findings
The tumor consisted of a peripheral epithelial area and a
central myxoedematous area. The peripheral epithelial
area consisted of cord-like and sheet-like structures of pro-
liferating carcinoma cells having a cuboidal or oval-
shaped nucleus. The central myxoedematous and chon-
droid-looking matrix contained an extensive area of
necrosis, but no definite chondrocytes or osseous differ-
entiation (Figs. 2, 3). Ductal carcinoma in situ (DCIS)
with comedo necrosis was found adjacent to the main
tumor. Immunohistochemically, the tumor cells in both
the peripheral epithelial area and the central myxoedema-
tous area were negative for estrogen receptor (ER), proges-
terone receptor (PgR) and Her2. In addition, the tumor
cells of both areas stained positively for both vimentin
and S-100 protein (Fig. 4), and they also showed partial
positive staining for each of cytokeratin AE1/AE3, CK7,
CK8 and CK19 (Fig. 5). Conversely, the tumor cells of
both areas stained negatively for each of α-smooth muscle
antigen (α-SMA), p63 and glial fibrillary acidic protein
(GFAP), which were myoepithelial cell markers. The
tumor cells were also negative for each of the basal mark-
ers, i.e., CK5/6, CK14, CK17, and epidermal growth factor
receptor (EGFR). Appropriate human breast cancers
known to express ER, PgR and Her2 were included in each
slide run. The luminal cells of non-tumorous adjacent
ducts were positive with ER and PgR as internal controls.
The myoepithelial cells of adjacent non-tumorous ducts
and acini were also positive with α-SMA, p63, CK5/6,
CK14 and CK17. Detailed information of the immunohis-
tochemistry procedures and the antibodies used was listed
Computed tomography scan imaging (CT) of the tumor Figure 1
Computed tomography scan imaging (CT) of the tumor. 
Contrast-enhanced CT revealed, in the right lateral-upper 
quadrant, an irregularly shaped, 2,5 cm tumor showing 
peripheral ring-shaped contrast enhancement.World Journal of Surgical Oncology 2008, 6:60 http://www.wjso.com/content/6/1/60
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in the Table 1. In special staining, the tumor stroma
stained positive with alcian blue (pH2.5), which was par-
tially eliminated by digestion with hyaluronidase.
Clinical course
Axillary lymph node dissection was performed on the
basis of a definitive diagnosis of MPC of the breast, but
there were no findings of metastasis. The remaining breast
tissue was irradiated with a total of 50 Gray. Postoperative
adjuvant chemotherapy was recommended, but the
patient refused this approach and it was thus not admin-
istered. Ten months after the axillary surgery, multiple
metastases and liver metastasis were diagnosed, and the
patient died 8 months after recurrence of the disease.
Discussion
Epithelial-mesenchymal transition has been reported to
be an etiological factor in metaplastic carcinoma [7]. The
overt carcinoma cells of almost all of the MPC breast can-
cer cases reported in Japan were positive for both epithe-
lial cell markers and mesenchymal cell markers (Table 2).
Electron microscope findings and the results of immuno-
histochemical studies were reported to indicate that MPC
is of myoepithelial cell origin [1,8]. On the other hand,
Okuyama et al. examined specimens from 8 patients and
reported that the overt carcinoma cells of all of those cases
were negative for myoepithelial cell markers [3]. Moreo-
ver, Only 4 of the 27 patients in Japan was positive for
myoepithelial cell markers. In the patient we have
described, as well, the overt carcinoma cells were positive
for vimentin, S-100 protein and cytokeratins (AE1/AE3,
CK7, CK8 and CK19). They showed negative staining for
α-SMA, p63, CK5/6 and GFAP, which are myoepithelial
cell markers. p63 has been reported to be useful as diag-
nostic marker for metaplastic carcinoma [9,10]. It was
reported that the carcinoma cells with spindle and/or
squamous differentiation in metaplastic carcinoma
showed positive staining for p63. The malignant compo-
nent with no squamous or sarcomatous differentiation in
MPC of our patient might cause negative staining for p63.
Low-magnification view of the tumor Figure 2
Low-magnification view of the tumor. The central myxoede-
matous area contained an extensive area of necrosis at its 
center (HE).
High-magnification view of the peripheral epithelial area (a) and the central area (b) of the tumor Figure 3
High-magnification view of the peripheral epithelial area (a) and the central area (b) of the tumor. The peripheral epithelial area 
consisted of cord-like and sheet-like structures of proliferating carcinoma cells having a cuboidal to oval-shaped nucleus. In the 
central areas of the tumor, sparse distribution of oval tumor cells was observed (HE).World Journal of Surgical Oncology 2008, 6:60 http://www.wjso.com/content/6/1/60
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Our patient's MPC exhibited the same cell marker profile
as that reported by Okuyama et al., showing the properties
of both epithelial cells and mesenchymal cells. It was
reported that the results of immunohistochemistry dif-
fered between the peripheral epithelial area and the cen-
tral myxoedematous area. In the central myxoedematous
area, which can be thought to be causing metaplasia,
down-regulation of epithelial markers and up-regulation
of mesenchymal markers were observed [1,4,5,11]. On
the contrary, for our patient, the peripheral epithelial area
and the central my edematous area showed no differences
in their staining profiles. Recent molecular studies have
shown the monoclonal origin of carcinosarcoma of the
breast, as the carcinomatous and sarcomatous elements
share common genetic alterations [12,13]. These observa-
tions support the hypothesis that the matrix-producing
carcinoma may be derived from a single totipotent stem
cell.
Immunohistochemical staining for vimentin of the peripheral epithelial area (a) and the central myxoedematous area (b) Figure 4
Immunohistochemical staining for vimentin of the peripheral epithelial area (a) and the central myxoedematous area (b). The 
tumor cells of the both area stained positively for vimentin.
Immunohistochemical staining for cytokeratin AE1/AE3 of the peripheral epithelial area (a) and the central myxoedematous  area (b) Figure 5
Immunohistochemical staining for cytokeratin AE1/AE3 of the peripheral epithelial area (a) and the central myxoedematous 
area (b). The tumor cells of the both area stained positively for cytokeratin AE1/AE3.World Journal of Surgical Oncology 2008, 6:60 http://www.wjso.com/content/6/1/60
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Our patient had triple-negative breast cancer with regard
to ER, PgR and Her2. In addition, it is interesting that
almost all of the reported Japanese cases of MPC of the
breast were triple-negative. It is said that most cases of
metaplastic carcinoma are also triple-negative breast can-
cer [14,15], and this is important in terms of elucidating
the etiology of the metaplastic change. Ninomiya et al.,
reported that one of their two cases of MPC of the breast
was the basal phenotype [5]. McCarthy et al., generated a
conditional mouse model of BRCA1  deficiency. Mam-
mary tumors that developed in these mice had basal and
metaplastic characteristics in the form of spindle cell and
squamous cell differentiation. Most of the tumors were
negative for ER, PgR and Her2 [6]. Additionally, a recent
report has shown that epithelial mesenchymal transition-
like changes occurred preferentially in the basal-like sub-
type of breast carcinomas [16]. Furthermore, subpopula-
tions of cancer cells with stem cell properties are especially
frequent within basal-like breast cell lines [17]. Stem cell-
like breast cell lines are also able to undergo epithelial
mesenchymal transition [18]. These data suggest that
basal-like cancer cells may undergo epithelial mesenchy-
mal transition with intrinsic phenotype of cancer stem
cells. Although most cases of triple-negative breast cancer
have the basal-like phenotype [6], MPC of our patient had
lack of any markers for myoepithelial cell type and basal-
like cell type. BRCA1 has been shown to play an impor-
tant role in mammary differentiation and the loss of
BRCA1  function resulted in the accumulation of cells
expressing the stem/progenitor marker ALDH-1 [19].
Although the BRCA1 status of our patient has not been
identified, it was suggested the possibility that the tumor
cells of our MPC might be blocked differentiation with
expansion of undifferentiated cell compartment.
Okuyama et al., reported that the incidence of MPC of the
breast was 0.05% in Japan [4]. Our search of the main Jap-
anese medical journals found a total of 27 cases of MPC
of the breast reported in Japan to date, including our
present patient [3-5,11]. Imaging diagnosis by contrast-
enhanced CT and contrast-enhanced MRI have revealed
that this disease is characterized by a ring structure in its
periphery. For that reason, it was concluded that it is nec-
essary to consider the possibility of MPC of the breast
when such image findings are obtained [3]. In our present
patient, as well, contrast-enhanced CT revealed an irregu-
larly shaped, 2.5 cm tumor showing peripheral ring-
shaped contrast enhancement.
Most MPC of the breast are triple-negative, and postoper-
ative adjuvant chemotherapy is often administered [13].
However, some studies have shown this therapy to have
Table 1: Characteristics of the overt carcinoma cells in matrix-producing carcinoma of the breast in Japan
ER PgR Her2 EMA AE1/AE3 Desmin α-SMA GFAP p63 S-100 Vimentin
(+) 0 1 0 16 20 0 4 1 0 15 17
(-) 23 22 14 0 1 11 15 0 1 0 3
ER: Estrogen receptor
PgR: Progesterone receptor
Her2: Human epidermal growth factor 2
EMA: epithelial membrane antigen
GFAP: glial fibrillay acidic protein
SMA: α-smooth muscle actin
Table 2: Sources, dilution and pretreatment of antibodies used
Antibody Clone Manufacturer Dilution Pretreatment
ER 1D5 DakoCytomation, USA 1:50 boiling (pH9.0, 40 min)
PgR PgR636 DakoCytomation, USA 1:800 boiling (pH9.0, 40 min)
HER2 DakoCytomation, USA Prediluted (Hercep test) boiling (pH6.0, 40 min)
CK5/6 D5/16B4 DakoCytomation, Denmark 1:100 autoclave (pH6.0, 10 min)
CK14 LL002 NeoMarkers, USA 1:100 autoclave (pH6.0, 10 min)
CK17 E3 DakoCytomation, Denmark 1:40 autoclave (pH6.0, 10 min)
EGFR 2-18C9 DakoCytomation, USA Prediluted (pharmDX kit) proteinase K (room temperature, 5 min)
AE1/AE3 AE/AE3 DakoCytomation, Denmark 1:50 pronase (37 C, 15 min)
CK7 OV-TL12/30 DakoCytomation, Denmark 1:50 pronase (37 C, 15 min)
CK8 35βH11 DakoCytomation, USA 1:50 pronase (37 C, 15 min)
CK19 RCK108 DakoCytomation, Denmark 1:50 autoclave (pH6.0, 10 min)
α-SMA 1A4 DakoCytomation, Denmark 1:100
P63 4A4 DakoCytomation, Denmark 1:50 autoclave (pH6.0, 10 min)
GFAP 6F2 DakoCytomation, Denmark 1:100Publish with BioMed Central    and   every 
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been ineffective, and further research on this issue is war-
ranted.
The prognosis of MPC of the breast is said to be better
than that of other carcinomas that are accompanied by
osteocartilaginous metaplasia [20,21]. Wargotz et al.,
reported a 5-year survival rate of 68% for MPC of the
breast [1], but the number of reported cases has been
small and the prognosis thus remains unclear. Our patient
refused postoperative adjuvant chemotherapy, and dis-
tant metastasis was detected at 10 months after the partial
mastectomy. In the future it will be necessary to study a
larger number of patients with MPC of the breast and fur-
ther elucidate the clinicopathological characteristics of
this malignancy.
Conclusion
There have been reports that MPC of the breast is of
myoepithelial cell origin or basal cell origin. However, the
findings for our present patient suggested that MPC might
be produced as a result of the undifferentiation process.
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